Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

161 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Bochtler T, Reiling A, Endris V, Hielscher T, Volckmar AL, Neumann O, Kirchner M, Budczies J, Heukamp LC, Leichsenring J, Allgäuer M, Kazdal D, Löffler H, Weichert W, Schirmacher P, Stenzinger A, Krämer A. Bochtler T, et al. Among authors: budczies j. Int J Cancer. 2020 Jun 1;146(11):3053-3064. doi: 10.1002/ijc.32882. Epub 2020 Mar 11. Int J Cancer. 2020. PMID: 31970771 Free article.
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G. Darb-Esfahani S, et al. Among authors: budczies j. Breast Cancer Res. 2009;11(5):R69. doi: 10.1186/bcr2363. Breast Cancer Res. 2009. PMID: 19758440 Free PMC article. Clinical Trial.
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression.
Hilvo M, Denkert C, Lehtinen L, Müller B, Brockmöller S, Seppänen-Laakso T, Budczies J, Bucher E, Yetukuri L, Castillo S, Berg E, Nygren H, Sysi-Aho M, Griffin JL, Fiehn O, Loibl S, Richter-Ehrenstein C, Radke C, Hyötyläinen T, Kallioniemi O, Iljin K, Oresic M. Hilvo M, et al. Among authors: budczies j. Cancer Res. 2011 May 1;71(9):3236-45. doi: 10.1158/0008-5472.CAN-10-3894. Epub 2011 Mar 17. Cancer Res. 2011. PMID: 21415164
Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.
Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, Rody A, Budczies J, Brase JC, Mehta MK, Bojar H, Ataseven B, Karn T, Weiss E, Zahm DM, Khandan F, Dietel M, Loibl S. Darb-Esfahani S, et al. Among authors: budczies j. Br J Cancer. 2012 Nov 20;107(11):1892-900. doi: 10.1038/bjc.2012.475. Epub 2012 Oct 18. Br J Cancer. 2012. PMID: 23079573 Free PMC article.
Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.
Müller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, Winzer KJ, Dietel M, Weichert W, Denkert C. Müller BM, et al. Among authors: budczies j. BMC Cancer. 2013 Apr 30;13:215. doi: 10.1186/1471-2407-13-215. BMC Cancer. 2013. PMID: 23627572 Free PMC article.
161 results